1. Home
  2. CAC vs KALV Comparison

CAC vs KALV Comparison

Compare CAC & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Camden National Corporation

CAC

Camden National Corporation

HOLD

Current Price

$43.09

Market Cap

680.5M

Sector

Finance

ML Signal

HOLD

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$16.32

Market Cap

551.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAC
KALV
Founded
1875
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
680.5M
551.2M
IPO Year
1997
N/A

Fundamental Metrics

Financial Performance
Metric
CAC
KALV
Price
$43.09
$16.32
Analyst Decision
Buy
Strong Buy
Analyst Count
3
8
Target Price
$47.33
$26.43
AVG Volume (30 Days)
64.9K
1.8M
Earning Date
01-27-2026
11-10-2025
Dividend Yield
3.90%
N/A
EPS Growth
9.13
N/A
EPS
3.49
N/A
Revenue
$215,172,000.00
$1,426,000.00
Revenue This Year
$44.50
N/A
Revenue Next Year
$7.03
$204.16
P/E Ratio
$12.35
N/A
Revenue Growth
27.50
N/A
52 Week Low
$34.53
$7.30
52 Week High
$47.55
$17.28

Technical Indicators

Market Signals
Indicator
CAC
KALV
Relative Strength Index (RSI) 69.15 67.20
Support Level $41.38 $13.28
Resistance Level $41.60 $16.80
Average True Range (ATR) 1.16 1.09
MACD 0.29 0.28
Stochastic Oscillator 93.26 79.32

Price Performance

Historical Comparison
CAC
KALV

About CAC Camden National Corporation

Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

Share on Social Networks: